Targeted Blockage! Sansure solution for detecting SARS-CoV-2 variant “Omicron”
On local time November 26, WHO held an emergency session and released a statement in which the SARS-CoV-2 variant B.1.1.529 was listed as a “Variant of Concern” and named after the Greek letter Omicron. According to WHO, the Omicron variant was first reported in South Africa. Preliminary studies showed that the variant has increased the risk of SARS-CoV-2 infection in human.
In response to Omicron, the latest variant of SARS-CoV-2, Sansure Biotech’s bioinformatics experts have carried out emergent analysis of the mutation sites of the variant and reviewed the testing regions of the existing products of the company. Ten (10) genetic sequences published on November 25 and 123 genetic sequences published at 12:00 on November 28, 2021 were followed up, analyzed and relevant information was updated. It has been confirmed that Sansure Biotech’s Novel Coronavirus(2019-nCoV) Nucleic Acid Diagnostic Kit (No.S3102E, S3113E, S3123E, S3125E) can detect the presently uploaded variant’s sequence without escape or off-target effect.
Sansure Biotech has been constantly keeping an eye on the dynamics of the global pandemic of COVID-19 since its outbreak. In Africa, one of the major business markets of Sansure Biotech, the company has been engaged in numerous commercial intercourses and collaborations, including China’s foreign aid projects and WHO’s development programs in African, with nearly 50 countries and regions, such as Ghana, Gabon, Togo, Benin, Egypt, and Ethiopia. Sansure Biotech has, since the year 2020 to date, dispatched dozens of employees to African countries such as Ghana and Gabon to help hundreds of laboratories to build and improve their nucleic acid testing capacity for the prevention and control of the pandemic of COVID-19.
So far, Sansure’s full-scenario solution has served more than 160 countries and regions throughout the world and become one of the leading nucleic acid assay solutions that have been used by numerous countries worldwide for its capability to accurately detect popular SARS-CoV-2 variants such as Alpha, Beta, Gamma, Delta, Lambda, Omicron, and the newly discovered porcine deltacoronavirus (Hu-PDCoV) and canine coronavirus HuPn-2018 (CCoV-HuPn-2018) that have the potential to infect human. In the future, Sansure Biotech will closely follow up the latest trend of SARS-CoV-2 variants worldwide and improve its products’ specificity, accuracy and sensitivity in the monitoring of SARS-CoV-2 for continuously making contribution to the prevention and control of the pandemic of COVID-19.
